sales@intentmarketresearch.com
+1 463-583-2713
As per Intent Market Research, the Chemiluminescence Immunoassay Market was valued at USD 12.6 billion in 2023 and will surpass USD 20.2 billion by 2030; growing at a CAGR of 7.0% during 2024 - 2030.
The report focuses on estimating the current market potential in terms of the total addressable market for all the segments, sub-segments, and regions. In the process, all the high-growth and upcoming technologies were identified and analyzed to measure their impact on the current and future market. The report also identifies the key stakeholders, their business gaps, and their purchasing behavior. This information is essential for developing effective marketing strategies and creating products or services that meet the needs of the target market. The report also covers a detailed analysis of the competitive landscape which includes major players, their recent developments, growth strategies, product benchmarking, and manufacturing operations among others. Also, brief insights on start-up ecosystem and emerging companies are also included as part of this report.
The report will help you answer some of the most critical questions in the Chemiluminescence Immunoassay Market. A few of them are as follows:
Report Features |
Description |
Market Size (2023) |
USD 12.6 billion |
Forecasted Value (2030) |
USD 20.2 billion |
CAGR (2024 – 2030) |
7.0% |
Base Year for Estimation |
2023 |
Historic Year |
2022 |
Forecast Period |
2024 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Chemiluminescence Immunoassay Market By Product (Instrument, Consumable), By Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence, Electrochemiluminescence Immunoassay (ECLI)), By Application (Infectious Disease, Oncology, Cardiology, Allergy Diagnostics, Autoimmune Disorders, Blood Screening, Bone & Mineral Disorders, Toxicology, Newborn Screening, Oncology), By End Use (Hospitals, Clinical Laboratories, Pharmaceuticals & Biotechnology Companies and Contract Research Organizations) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Spain, Italy & Rest of Europe), Asia Pacific (China, Japan, South Korea, India, and rest of Asia Pacific), Latin America (Brazil, Argentina, & Rest of Latin America), Middle East & Africa (Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA) |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
1.Introduction |
1.1.Market Definition |
1.2.Scope of the Study |
1.3.Research Assumptions |
1.4.Study Limitations |
2.Research Methodology |
2.1.Research Approach |
2.1.1.Top-Down Method |
2.1.2.Bottom-Up Method |
2.1.3.Factor Impact Analysis |
2.2.Insights & Data Collection Process |
2.2.1.Secondary Research |
2.2.2.Primary Research |
2.3.Data Mining Process |
2.3.1.Data Analysis |
2.3.2.Data Validation and Revalidation |
2.3.3.Data Triangulation |
3.Executive Summary |
3.1.Major Markets & Segments |
3.2.Highest Growing Regions and Respective Countries |
3.3.Impact of Growth Drivers & Inhibitors |
3.4.Regulatory Overview by Country |
4.Chemiluminescence Immunoassay Market, by Product (Market Size & Forecast: USD Million, 2022 – 2030) |
4.1.Instruments |
4.2.Consumables |
5.Chemiluminescence Immunoassay Market, by Technology (Market Size & Forecast: USD Million, 2022 – 2030) |
5.1.Microparticle Chemiluminescence Immunoassay |
5.2.Electrochemiluminescence Immunoassay (ECLI) |
5.3.Chemiluminescence Enzyme Technology (CLEIA) |
6.Chemiluminescence Immunoassay Market, by Application (Market Size & Forecast: USD Million, 2022 – 2030) |
6.1.Cardiology |
6.2.Endocrinology |
6.3.Respiratory |
6.4.Infectious Disease |
6.5.Allergy Diagnostics |
6.6.Autoimmune Disorders |
6.7.Newborn Screening |
6.8.Bone & Mineral Disorders |
6.9.Toxicology |
6.10.Blood Screening |
6.11.Gastroenterology |
6.12.Metabolic Disorder |
6.13.Therapeutic Drug Monitoring |
6.14.Neurology |
6.15.Oncology |
6.16.Other Applications |
7.Chemiluminescence Immunoassay Market, by End Use (Market Size & Forecast: USD Million, 2022 – 2030) |
7.1.Hospitals |
7.2.Clinical Laboratories |
7.3.Contract Research Organizations |
7.4.Pharmaceuticals & Biotechnology |
8.Regional Analysis (Market Size & Forecast: USD Million, 2022 – 2030) |
8.1.Regional Overview |
8.2.North America |
8.2.1.Regional Trends & Growth Drivers |
8.2.2.Barriers & Challenges |
8.2.3.Opportunities |
8.2.4.Factor Impact Analysis |
8.2.5.Technology Trends |
8.2.6.North America Chemiluminescence Immunoassay Market, by Product |
8.2.8.North America Chemiluminescence Immunoassay Market, by Technology |
8.2.9.North America Chemiluminescence Immunoassay Market, by Application |
8.2.10.North America Chemiluminescence Immunoassay Market, by End Use |
*Similar segmentation will be provided at each regional level |
8.3.By Country |
8.3.1.US |
8.3.1.1.US Chemiluminescence Immunoassay Market, by Product |
8.3.1.2.US Chemiluminescence Immunoassay Market, by Technology |
8.3.1.3.US Chemiluminescence Immunoassay Market, by Application |
8.3.1.4.US Chemiluminescence Immunoassay Market, by End Use |
8.3.2.Canada |
8.3.3.Mexico |
*Similar segmentation will be provided at each country level |
8.4.Europe |
8.5.APAC |
8.6.Latin America |
8.7.Middle East & Africa |
9.Competitive Landscape |
9.1.Overview of the Key Players |
9.2.Competitive Ecosystem |
9.2.1.Platform Manufacturers |
9.2.2.Subsystem Manufacturers |
9.2.3.Service Providers |
9.2.4.Software Providers |
9.3.Company Share Analysis |
9.4.Company Benchmarking Matrix |
9.4.1.Strategic Overview |
9.4.2.Product Innovations |
9.5.Start-up Ecosystem |
9.6.Strategic Competitive Insights/ Customer Imperatives |
9.7.ESG Matrix/ Sustainability Matrix |
9.9.Manufacturing Network |
9.9.1.Locations |
9.9.2.Supply Chain and Logistics |
9.9.3.Product Flexibility/Customization |
9.9.4.Digital Transformation and Connectivity |
9.9.5.Environmental and Regulatory Compliance |
9.9.Technology Readiness Level Matrix |
9.10.Technology Maturity Curve |
9.11.Buying Criteria |
10.Company Profiles |
10.1.Roche Diagnostics |
10.1.1.Company Overview |
10.1.2.Company Financials |
10.1.3.Product/Service Portfolio |
10.1.4.Recent Developments |
10.1.5.IMR Analysis |
*Similar information will be provided for other companies |
10.2.Danaher Corporation |
10.3.Siemens Healthineers |
10.4.Abbott Laboratories |
10.5.DiaSorin |
10.6.Shenzhen Mindray |
10.7.Sysmex Corporation |
10.8.Werfen |
10.9.Maccura Biotechnology |
10.10.Quidel Ortho Corporation |
11.Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Chemiluminescence Immunoassay Market. In the process, the analysis was also done to estimate the parent market and relevant adjacencies to measure the impact of them on the chemiluminescence immunoassay market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the chemiluminescence immunoassay ecosystem. The primary research objectives included:
A combination of top-down and bottom-up approaches was utilized to estimate the overall size of the chemiluminescence immunoassay market. These methods were also employed to estimate the size of various subsegments within the market. The market size estimation methodology encompassed the following steps:
To ensure the accuracy and reliability of the market size estimates, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size estimates.